EP Patent

EP3275885A1 — Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same

Assigned to Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft · Expires 2018-01-31 · 8y expired

What this patent protects

The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. …

USPTO Abstract

The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.

Drugs covered by this patent

Patent Metadata

Patent number
EP3275885A1
Jurisdiction
EP
Classification
Expires
2018-01-31
Drug substance claim
No
Drug product claim
No
Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.